'Personalised medicine' plans would reduce need for chemotherapy by 34% Friday 7 November 2014 PDF Print Personalised medicine would reduce chemotherapy use in breast cancer patients by 34% , according to a new study from Vlerick Business School. The study says that if women with breast cancer underwent a genetic test before treatment, the need for chemotherapy use in patients would drop. Personalised medicine is a medical model that proposes the customization of healthcare using molecular analysis – this means that each treatment can be tailored to individual patients. By combining data from molecular diagnostic tests with a patient’s medical history and circumstances, healthcare providers can develop targeted prevention and treatment plans. The same study also shows that genetic tests would prevent 17.000 heart strokes every year. Professor Walter Van Dyck says: ‘’Personalized medicine is not only able to deliver better medicine through better diagnosis and treatment. It also allows early detection of disease at the molecular level. This enhances the chances of early, better treatment. It saves costs to society by keeping patients out of later, more expensive treatments.’’ ‘’Healthcare would be much more cost-effective to society if there was an investment shift from the ‘hospital based in-patient’ modality, to a ‘physician based out-patient’ infrastructure. This would allow the population to be stratified more much earlier into high/low risk groups by applying a combination of digital health records, patient history and genetic testing.’’ If you would like to read the study or to speak to Prof. Van Dyck please contact Alexandra Dobocan at firstname.lastname@example.org or call +44 (0)1582 790 709 This press release was distributed by ResponseSource Press Release Wire on behalf of BlueSky Public Relations Ltd in the following categories: Health, Medical & Pharmaceutical, for more information visit http://pressreleasewire.responsesource.com/about.